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Freitas and co-workers at Syntex Research have reported recently that zidovu- 
dine (AZT) potentiates the antiviral activity of ganciclovir (DHPG) against a clinical 
isolate of human cytomegalovirus (HCMV) and interacts in an additive manner 
with a laboratory strain (AD169) of the same virus (Freitas et al., 1993). In contrast 
to our studies (Prichard et al., 199 !) and those of others (Tian et al., 1991; Medina et 
al., 1992), Freitas and co-workers did not observe in vitro synergistic toxicity with 
AZT and DHPG using a new analytical method. A possible explanation for these 
differences may be attributable to the different experimental parameters selected. 
Freitas and associates assayed metabolic activity in mitochondria with MTT as- 
says, both Tian et al. and Medina et al. assessed cytotoxicity by determining the 
number of viable cells (trypan blue exclusion) and total cellular protein (bicincho- 
linic acid method), whereas we chose to measure cytotoxicity by counting viable cells 
and by measuring the effects of drugs on plating efficiencies. In vitro studies aside, 
clinical experience has clearly revealed, however, that the concomitant administra- 
tion of AZT and DHPG is contra-indicated (Jacobson et al., 1988; Hochster et al., 
1990; Millar et al., 1990). A newly developed regimen does allow the co-administra- 
tion of AZT and DHPG under certain controlled conditions (Causey, 1991). In this 
protocol, AZT may be given concomitantly with DHPG if the absolute granulocyte 
counts are above 750//A. If the absolute granulocyte counts are initially below 750//d 
or fall below 750/#1, AZT is discontinued, while DHPG is administered. This proto- 
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col minimizes potential toxicity by avoiding concurrent dosing with AZT and 
DHP G when hematologic cytotoxicity becomes evident. 
We are futher concerned by the misrepresentation of our analytical method 
(MacSynergy T M  II) by Freitas and co-workers. In their publication, the authors 
describe a step in our analysis as follows: "This theoretical additive surface is calcu- 
lated based on a series of assumptions which must be made about additivity of the 
two drugs, and has to be predicted beyond the IC50 by using the equations in 
Prichard and Shipman's model. Even if one were to assume non-additive drug 
effects, the method still requires extrapolation. Such extrapolation will severely im- 
pact the adequacy of the analysis." They continue, "By avoiding the assumptions 
made by Prichard and Shipman (1990), as well as by Tian et al. (1991), the present 
analyses are necessarily more conservative and consequently reduce the false-posi- 
tive rate." These statements are inaccurate in several respects and are related to 
important details missing from the Freitas et al. paper. The analysis of drug interac- 
tions attempts to characterize synergistic (greater than additive) or antagonistic 
(lesser than additive) effects. Therefore, "additive" effects must be defined by any 
analytical model including the new model described in the Freitas et al. offering. 
Two fundamental and non identical assumptions are commonly used to calculate 
theoretical additive effects (Loewe, 1953; Berenbaum, 1981; Chou and Talalay 
1984; Greco et al., 1990; Greco et al., 1992; Prichard and Shipman, 1992). Our 
analytical method uses the "Bliss independence" assumption. This is the only as- 
sumption required to calculate theoretical additive effects that does not extrapolate 
any experimental data. Therefore, the different conclusions reached by our labora- 
tory and the Syntex laboratory cannot be due to extrapolation as suggested by 
Freitas et al. 
We are unable to fully evaluate the analytical model presented by Freitas et al. in 
as much as essential details are missing from the report. The statistical analysis is 
presented in minute detail, yet the fundamental assumption of additivity is not 
given. Their unstated assumption is important as the "Loewe additivity" assump- 
tion requires extrapolation and/or curve fitting and would affect the authors' con- 
clusions if used. An additional troubling aspect of the Freitas et al. analytical model 
is that it seeks a "consistent deviation from additivity across the entire dose-re- 
sponse surface". Typically, synergy or antagonism are observed at a restricted sub- 
set of drug concentrations (for examples, see Lambert et al., 1993; Prichard et al., 
1993). A statistic indicating the lack of a consistent response across the entire dose- 
response surface should not be interpreted as indicating that no synergism or antag- 
onism exists. We trust that further studies are in progress to confirm the results 
produced by the Freitas et al. experimental model and that important details about 
this model will be forthcoming. 
Based on their newly described analytical methods, Freitas and colleagues suggest 
that ganciclovir can safely be used with zidovudine for the treatment of  opportunis- 
tic HCMV infection in AIDS patients. Our interpretation of the published preclini- 
cal and clinical literature and our own experimental data would strongly suggest 
that clinical investigators should proceed with caution when considering combina- 
tions of D H P G  with licensed or experimental anti-HIV drugs. 
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